OPINION
Healius (HLS) $1.355
HLS –6.55%: Was weaker today on a result that had been flagged at the end of last year. In a trading update on the 15th November, HLS provided guidance for this result, so we had a pretty good handle on what they should deliver. Read moreHealius (HLS) $1.335
HLS -16.04%: When it rains, it pours! HLS today provided commentary at their AGM via the CEO’s presentation that was disappointing, insofar as while they said that pathology volumes have increased by 4.5% for the year to date, with revenues growing by 5.9%, they put a big caveat on how that revenue would translate into earnings due to cash draw from investments and inflationary pressures, in terms of goods and labour. Read moreHealius Ltd (HLS) $1.85
Pathology giant HLS surged +7.25% on Tuesday, making it the top performer on the main board. In the process, it posted fresh 12-month highs - yet interestingly, no news was crossing the wires. Analysts dislike this company as they did the resources before China fuelled a strong short covering rally: 4 Sells & 6 Holds with an average price target (PT) of $1.55, well below yesterday's close – this data can be seen on the MM website. Read moreHealius (HLS) $1.73
HLS +7.45% was up nicely today on news it has agreed to sell its imaging unit Lumus to U.S-based Affinity Equity Group for $965 million. As per our last note on HLS, we expected a sale price of circa. $700 million. We think this is a good price given Lumus has been loss-making for the past 2 years. Read moreHealius (HLS) $1.65
HLS -2.65% was hit hard early today, down as much as 9% at the lows before recovering. The drop was a result of Barrenjoey downgrading the stock to sell with a $1.37 price target, a bearish view that is actually aligned with the majority in the market i.e. more analysts have a negative outlook on HLS. Read moreActive Growth Portfolio – Amendments
We are making two changes to the Active Growth Portfolio. Read more
